State of Alaska Department of Revenue Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)

State of Alaska Department of Revenue raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,830 shares of the medical device company’s stock after buying an additional 105 shares during the period. State of Alaska Department of Revenue’s holdings in DexCom were worth $5,801,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of DXCM. Advisors Asset Management Inc. lifted its holdings in DexCom by 10.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 16,291 shares of the medical device company’s stock valued at $1,520,000 after buying an additional 1,588 shares in the last quarter. Alps Advisors Inc. boosted its holdings in shares of DexCom by 6.3% in the third quarter. Alps Advisors Inc. now owns 12,877 shares of the medical device company’s stock valued at $1,201,000 after purchasing an additional 763 shares during the period. Lido Advisors LLC grew its stake in DexCom by 1,485.9% in the third quarter. Lido Advisors LLC now owns 56,298 shares of the medical device company’s stock worth $5,253,000 after purchasing an additional 52,748 shares in the last quarter. Seven Eight Capital LP increased its holdings in DexCom by 5.0% during the 3rd quarter. Seven Eight Capital LP now owns 24,134 shares of the medical device company’s stock worth $2,252,000 after purchasing an additional 1,150 shares during the period. Finally, Royal London Asset Management Ltd. raised its position in DexCom by 4.9% during the 3rd quarter. Royal London Asset Management Ltd. now owns 148,426 shares of the medical device company’s stock valued at $13,849,000 after purchasing an additional 6,954 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, Director Bridgette P. Heller sold 1,000 shares of the stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $138.30, for a total value of $6,864,243.90. Following the sale, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at $39,262,401.90. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the sale, the director now directly owns 25,349 shares in the company, valued at $2,878,378.95. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,735 shares of company stock valued at $7,619,347. 0.30% of the stock is owned by company insiders.

DexCom Stock Down 1.4 %

NASDAQ:DXCM opened at $110.91 on Thursday. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a market cap of $44.11 billion, a PE ratio of 71.56, a P/E/G ratio of 2.75 and a beta of 1.16. The company’s 50 day moving average is $121.78 and its two-hundred day moving average is $125.47.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. Analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on DXCM. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. UBS Group boosted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Canaccord Genuity Group increased their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Raymond James boosted their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Finally, Redburn Atlantic initiated coverage on DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $140.33.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.